Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsU
The experimentally established mechanism targets of Tobramycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HPSE | Q9Y251 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | GJA1 | P17302 | 1/20 | 0.78 |
| ▸ | GJB2 | P29033 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tobramycin SCHEMBL17552533 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL17145817 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL19678587 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL12930900 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL17680145 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL12085526 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL15263385 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL3658310 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL22364334 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR | |
| Tobramycin SCHEMBL17759326 | 1.00 | ALOX15 (1.00) | ALOX15HPSECYP3A4GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272158-B2 | Compounds for treating biofilm infection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272158-B2 | Compounds for treating biofilm infection | CFTR, MUC1, ALG1 | ALOX15 3595/4885HPSE 1226/4885CYP3A4 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.